{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sahm K"],"funding":["Deutsche Forschungsgemeinschaft","Gemeinnützige Hertie-Stiftung","Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation)","Deutsche Forschungsgemeinschaft (German Research Foundation)","Gemeinnützige Hertie-Stiftung (Hertie Foundation)","Else Kröner-Fresenius-Stiftung"],"pagination":["186"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10728097"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(1)"],"pubmed_abstract":["<h4>Background</h4>Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives.<h4>Methods</h4>A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients.<h4>Results</h4>MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade 4 without isocitratdehydrogenase (IDH) mutations have a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade 2 receive multiple sclerosis diagnos"],"journal":["Communications medicine"],"pubmed_title":["Concurrent gliomas in patients with multiple sclerosis."],"pmcid":["PMC10728097"],"funding_grant_id":["2019_EKMS.23","39404578","P1200013"],"pubmed_authors":["Eisele P","Bendszus M","Mildenberger I","Herold-Mende C","von Deimling A","Seliger C","Konig L","Zeiner PS","Meuth SG","Capper D","Sperk E","Schrimpf D","Sahm F","Sahm K","Tabatabai G","Platten M","Wick W","Breckwoldt MO","Ratliff M","Kessler T"],"additional_accession":[]},"is_claimable":false,"name":"Concurrent gliomas in patients with multiple sclerosis.","description":"<h4>Background</h4>Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives.<h4>Methods</h4>A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients.<h4>Results</h4>MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade 4 without isocitratdehydrogenase (IDH) mutations have a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade 2 receive multiple sclerosis diagnos","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-07-14T22:42:51.951Z","creation":"2026-06-26T03:07:05.686Z"},"accession":"S-EPMC10728097","cross_references":{"pubmed":["38110626"],"doi":["10.1038/s43856-023-00381-y"]}}